0 CHECKOUT

Pemphigus Vulgaris - Pipeline Review, H1 2015

  • ID: 3330524
  • June 2015
  • 59 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Biogen, Inc.
  • Genmab A/S
  • Immunomedics, Inc.
  • Novartis AG
  • MORE

Pemphigus Vulgaris - Pipeline Review, H1 2015

Summary

This, ‘Pemphigus Vulgaris - Pipeline Review, H1 2015’, provides an overview of the Pemphigus Vulgaris’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pemphigus Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pemphigus Vulgaris and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biogen, Inc.
  • Genmab A/S
  • Immunomedics, Inc.
  • Novartis AG
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Pemphigus Vulgaris Overview
Therapeutics Development
Pipeline Products for Pemphigus Vulgaris - Overview
Pipeline Products for Pemphigus Vulgaris - Comparative Analysis
Pemphigus Vulgaris - Therapeutics under Development by Companies
Pemphigus Vulgaris - Therapeutics under Investigation by Universities/Institutes
Pemphigus Vulgaris - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Pemphigus Vulgaris - Products under Development by Companies
Pemphigus Vulgaris - Products under Investigation by Universities/Institutes
Pemphigus Vulgaris - Companies Involved in Therapeutics Development
Biogen, Inc.
Genmab A/S
HanAll Biopharma Co., Ltd.
Immunomedics, Inc.
Novartis AG
Pemphigus Vulgaris - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
DP-C006 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HL-161 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ofatumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T-Cell Therapy for Pemphigus Vulgaris - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VAY-736 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
veltuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pemphigus Vulgaris - Recent Pipeline Updates
Pemphigus Vulgaris - Dormant Projects
Pemphigus Vulgaris - Product Development Milestones
Featured News & Press Releases
Oct 07, 2014: Stiefel, a GSK company, announces start of phase III study of subcutaneous ofatumumab for pemphigus vulgaris
Jul 04, 2013: Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Pemphigus Vulgaris, H1 2015
Number of Products under Development for Pemphigus Vulgaris - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Pemphigus Vulgaris - Pipeline by Biogen, Inc., H1 2015
Pemphigus Vulgaris - Pipeline by Genmab A/S, H1 2015
Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co., Ltd., H1 2015
Pemphigus Vulgaris - Pipeline by Immunomedics, Inc., H1 2015
Pemphigus Vulgaris - Pipeline by Novartis AG, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Pemphigus Vulgaris Therapeutics - Recent Pipeline Updates, H1 2015
Pemphigus Vulgaris - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Pemphigus Vulgaris, H1 2015
Number of Products under Development for Pemphigus Vulgaris - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Biogen, Inc.
Genmab A/S
HanAll Biopharma Co., Ltd.
Immunomedics, Inc.
Novartis AG

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Merck & Co., Inc.
  • Celgene Corporation
  • GlaxoSmithKline PLC
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • ViiV Healthcare